Novo Nordisk A/S (NYSE:NVO) Shares Sold by Shikiar Asset Management Inc.

Shikiar Asset Management Inc. lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,159 shares of the company’s stock after selling 15,085 shares during the period. Novo Nordisk A/S makes up approximately 2.2% of Shikiar Asset Management Inc.’s portfolio, making the stock its 16th largest position. Shikiar Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $8,272,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC boosted its stake in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $4,066,000. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $86,000. Finally, Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE:NVO opened at $78.74 on Friday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm’s 50 day moving average price is $98.33 and its 200 day moving average price is $117.69. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.